The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among ...

The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.

Forte Biosciences is being acquired by Argenx for $2.2 billion [$77/share], capping near-term upside. Click here to read my ...

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology ...

SE’s $2.2B Forte Biosciences, Inc. deal adds FB-102 to expand pipeline, but valuation & Vyvgart patent risks raise caution.

Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.

Argenx has agreed to acquire Forte Biosciences for $2.2 billion, the companies said, in a deal intended to expand the buyer’s ...

(NASDAQ:ARGX) said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity ...

Netherlands- and Belgium-based biotech argenx has agreed to buy US biotech Forte Biosciences for up to $2.2 billion, ...

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Argenx said Monday it would buy ...

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growthFB102 Phase 1b studies in vi ...